Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Dec 18;9(3):4102-4108.
doi: 10.18632/oncotarget.23468. eCollection 2018 Jan 9.

Pulmonary sarcomatoid carcinoma: University of Cincinnati experience

Nagla Abdel Karim  1 , James Schuster  2 , Ihab Eldessouki  1 , Ola Gaber  1 , Tariq Namad  3 , Jiang Wang  4 , Changchun Xie  5 , John C Morris  1
Affiliations

Pulmonary sarcomatoid carcinoma: University of Cincinnati experience

Nagla Abdel Karim et al. Oncotarget. .

Abstract

Objectives: To review the outcomes of treatment in patients with pulmonary sarcomatoid carcinoma (PSC) treated at the University of Cincinnati Medical Center (UCMC).

Results: There was no significant difference in survival of patients treated with chemotherapy alone (median, 256 days) compared to patients not undergoing treatment (median, 205.5 days). Patients who underwent surgery and adjuvant chemotherapy showed a trend in improvement of survival (median, 457.6 days). Patients requiring only surgery had the longest OS of 713.5 days.

Conclusions: Systemic chemotherapy alone did not improve survival in patients with PSC. Surgery provides the greatest overall survival benefit and adjuvant chemotherapy may also improve survival.

Methods: From 2000 to 2014, twenty-five patients with pathologically confirmed PSC were treated at UCMC. The outcomes were retrospectively analyzed by treatment with overall survival (OS) as the endpoint.

Keywords: chemotherapy; lung cancer; non-small cell lung cancer; sarcomatoid.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST No potential conflicts of interest exists.

Figures

Figure 1
Figure 1. Survival of sarcomatoid lung cancer patients (n = 25)
Figure 2
Figure 2. Forest Plot showing hazard ratio for different parameters
Smoking had the highest impact followed by stage, being the main detrimental factor for the type treatment the patient receives.
See this image and copyright information in PMC

References

    1. Ung M, Rouquette I, Filleron T, Taillandy K, Brouchet L, Bennouna J, Delord JP, Milia J, Mazières J. Characteristics and Clinical Outcomes of Sarcomatoid Carcinoma of the Lung. Clin Lung Cancer. 2016;17:391–397. https://doi.org/10.1016/j.cllc.2016.03.001. - DOI - PubMed
    1. Huang SY, Shen SJ, Li XY. Pulmonary sarcomatoid carcinoma: a clinicopathologic study and prognostic analysis of 51 cases. World J Surg Oncol. 2013;11:252. https://doi.org/10.1186/1477-7819-11-252. - DOI - PMC - PubMed
    1. Brambilla E, Travis WD, Colby TV, Corrin B, Shimosato Y. The new World Health Organization classification of lung tumours. Eur Respir J. 2001;18:1059–68. https://doi.org/10.1183/09031936.01.00275301. - DOI - PubMed
    1. Yendamuri S, Caty L, Pine M, Adem S, Bogner P, Miller A, Demmy TL, Groman A, Reid M. Outcomes of sarcomatoid carcinoma of the lung: a Surveillance, Epidemiology, and End Results Database analysis. Surgery. 2012;152:397–402. https://doi.org/10.1016/j.surg.2012.05.007. - DOI - PubMed
    1. Lin Y, Yang H, Cai Q, Wang D, Rao H, Lin S, Long H, Fu J, Zhang L, Lin P, Xu G, Rong T, Xiong X, et al. Characteristics and Prognostic Analysis of 69 Patients With Pulmonary Sarcomatoid Carcinoma. Am J Clin Oncol. 2016;39:215–22. https://doi.org/10.1097/COC.0000000000000101. - DOI - PubMed

LinkOut - more resources